• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Hyperfine Inc.

    2/14/22 11:18:38 AM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $HYPR alert in real time by email
    SC 13G 1 tm226422d1_sc13g.htm SC 13G

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

     

     

    SCHEDULE 13G

     

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    (Amendment No. )*

     

     

     

    Hyperfine, Inc.
    (Name of Issuer)

     

    Class A common stock
    (Title of Class of Securities)

     

    44916K106
    (CUSIP Number)

     

    December 31, 2021
    (Date of Event Which Requires Filing of this Statement)

     

     

     

    Check the Appropriate Box to Designate the Rule Pursuant to Which this Schedule Is Filed:

     

    ¨       Rule 13d-1(b)

     

    ¨       Rule 13d-1(c)

     

    x      Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    1.

    Names of Reporting Persons

     

    HC Sponsor LLC 

    2.

    Check The Appropriate Box if a Member of a Group (See Instructions)

     

    (a) ¨         (b) ¨

    3. SEC Use Only
    4.

    Citizenship or Place of Organization

     

    Cayman Islands 

    Number of Shares
    Beneficially Owned
    By Each Reporting
    Person With
    5.

    Sole Voting Power

     

    0 

    6.

    Shared Voting Power

     

    6,534,000(1) 

    7.

    Sole Dispositive Power

     

    0 

    8.

    Shared Dispositive Power

     

    6,534,000(1) 

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    6,534,000(1) 

    10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares ¨ 
    11.

    Percent of Class Represented By Amount in Row (9)

     

    11.8%(2) 

    12.

    Type of Reporting Person (See Instructions)

     

    OO 

     

    (1) Represents 5,534,000 Class A Shares held directly by HC Sponsor LLC and 1,000,000 Class A Shares held directly by the HC Affiliates.

     

    (2) Calculated based on 55,277,061 Class A Shares outstanding as of December 31, 2021, as reported on the Issuer’s final prospectus filed pursuant to Rule 424(b)(3) with the SEC on February 1, 2022.

     

     

     

    1.

    Names of Reporting Persons

     

    HealthCor Group, LLC 

    2.

    Check The Appropriate Box if a Member of a Group (See Instructions)

     

    (a) ¨         (b) ¨

    3. SEC Use Only
    4.

    Citizenship or Place of Organization

     

    New York 

    Number of Shares
    Beneficially Owned
    By Each Reporting
    Person With
    5.

    Sole Voting Power

     

    0 

    6.

    Shared Voting Power

     

    6,534,000(1) 

    7.

    Sole Dispositive Power

     

    0 

    8.

    Shared Dispositive Power

     

    6,534,000(1) 

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    6,534,000(1) 

    10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares ¨
    11.

    Percent of Class Represented By Amount in Row (9)

     

    11.8%(2) 

    12.

    Type of Reporting Person (See Instructions)

     

    OO 

     

    (1) Represents 5,534,000 Class A Shares held directly by HC Sponsor LLC and 1,000,000 Class A Shares held directly by the HC Affiliates.

     

    (2) Calculated based on 55,277,061 Class A Shares outstanding as of December 31, 2021, as reported on the Issuer’s final prospectus filed pursuant to Rule 424(b)(3) with the SEC on February 1, 2022.

     

     

     

    1.

    Names of Reporting Persons

     

    Arthur Bruce Cohen 

    2.

    Check The Appropriate Box if a Member of a Group (See Instructions)

     

    (a) ¨         (b) ¨

    3. SEC Use Only
    4.

    Citizenship or Place of Organization

     

    United States 

    Number of Shares
    Beneficially Owned
    By Each Reporting
    Person With
    5.

    Sole Voting Power

     

    0 

    6.

    Shared Voting Power

     

    6,534,000(1) 

    7.

    Sole Dispositive Power

     

    0 

    8.

    Shared Dispositive Power

     

    6,534,000(1) 

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    6,534,000(1) 

    10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares ¨
    11.

    Percent of Class Represented By Amount in Row (9)

     

    11.8%(2) 

    12.

    Type of Reporting Person (See Instructions)

     

    IN 

     

    (1) Represents 5,534,000 Class A Shares held directly by HC Sponsor LLC and 1,000,000 Class A Shares held directly by the HC Affiliates.

     

    (2) Calculated based on 55,277,061 Class A Shares outstanding as of December 31, 2021, as reported on the Issuer’s final prospectus filed pursuant to Rule 424(b)(3) with the SEC on February 1, 2022.

     

     

     

    1.

    Names of Reporting Persons

     

    Joseph Patrick Healey 

    2.

    Check The Appropriate Box if a Member of a Group (See Instructions)

     

    (a) ¨         (b) ¨

    3. SEC Use Only
    4.

    Citizenship or Place of Organization

     

    United States 

    Number of Shares
    Beneficially Owned
    By Each Reporting
    Person With
    5.

    Sole Voting Power

     

    0 

    6.

    Shared Voting Power

     

    6,534,000(1) 

    7.

    Sole Dispositive Power

     

    0 

    8.

    Shared Dispositive Power

     

    6,534,000(1) 

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    6,534,000(1) 

    10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares ¨ 
    11.

    Percent of Class Represented By Amount in Row (9)

     

    11.8%(2) 

    12.

    Type of Reporting Person (See Instructions)

     

    IN 

     

    (1) Represents 5,534,000 Class A Shares held directly by HC Sponsor LLC and 1,000,000 Class A Shares held directly by the HC Affiliates.

     

    (2) Calculated based on 55,277,061 Class A Shares outstanding as of December 31, 2021, as reported on the Issuer’s final prospectus filed pursuant to Rule 424(b)(3) with the SEC on February 1, 2022.

     

     

     

    Item 1(a). Name of Issuer
      Hyperfine, Inc.  
    Item 1(b). Address of the Issuer’s Principal Executive Offices
      351 New Whitfield Street
    Guilford, CT 06437
    Item 2(a). Names of Persons Filing
     

    This statement is filed on behalf of each of the following persons (collectively, the “Reporting Persons”):

     

    (i)            HC Sponsor LLC

     

    (ii)           HealthCor Group, LLC

     

    (iii)          Arthur Bruce Cohen

     

    (iv)          Joseph Patrick Healey 

    Item 2(b). Address of the Principal Business Office, or if none, Residence:
      55 Hudson Yards, 28th Floor
    New York, NY 10001
    Item 2(c). Citizenship
      See responses to Item 4 on each cover page.
    Item 2(d). Title of Class of Securities
      Class A common stock
    Item 2(e). CUSIP Number
      44916K106
    Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a(n):
      Not Applicable.

     

    Item 4.

    Ownership

     

    (a)          Amount beneficially owned: 

    See responses to Item 9 on each cover page. 

    (b)          Percent of Class:
    See responses to Item 11 on each cover page. 

    (c)          Number of shares as to which the Reporting Person has: 

    (i)           Sole power to vote or to direct the vote:  

    See responses to Item 5 on each cover page. 

    (ii)          Shared power to vote or to direct the vote: 

    See responses to Item 6 on each cover page. 

    (iii)         Sole power to dispose or to direct the disposition of:  

    See responses to Item 7 on each cover page. 

    (iv)         Shared power to dispose or to direct the disposition of: 

    See responses to Item 8 on each cover page.

     

     

     

     

      HC Sponsor LLC (the “Sponsor”) directly holds 5,534,000 Class A Shares (the “Founder Shares”) and entities affiliated with the Sponsor (the “HC Affiliates”) directly hold 1,000,000 Class A Shares (the “PIPE Shares”). The Sponsor is managed by its manager, HealthCor Sponsor Investments LLC, which is managed by its manager, HealthCor Group, LLC, which also indirectly manages the HC Affiliates. Arthur Cohen and Joseph Healey are the controlling members of HealthCor Group, LLC. As such, Messrs. Cohen and Healey have voting and investment discretion with respect to the securities held by each of HC Sponsor LLC and the HC Affiliates but disclaim beneficial ownership of such securities. The filing of this Statement shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any securities covered by this Statement.
    Item 5. Ownership of Five Percent or Less of a Class
      Not Applicable.
    Item 6. Ownership of More than Five Percent on Behalf of Another Person
      Not Applicable.
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company
      Not Applicable.
    Item 8. Identification and Classification of Members of the Group
      Not Applicable.
    Item 9. Notice of Dissolution of Group
      Not Applicable.
    Item 10. Certification
      Not Applicable.

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 14, 2022

     

      HC Sponsor LLC
       
      By: /s/ Christine Clarke
      Name: Christine Clarke
      Title: Authorized Signatory
       
      HealthCor Group, LLC
       
      By: /s/ Christine Clarke
      Name: Christine Clarke
      Title: Authorized Signatory
       
      /s/ Arthur B. Cohen
      Arthur B. Cohen
       
      /s/ Joseph P. Healey
      Joseph P. Healey

     

     

     

    EXHIBIT INDEX

     

    Exhibit No.   Description
    99.1   Joint Filing Agreement, dated as of February 14, 2022 by and among HC Sponsor LLC, HealthCor Group, LLC, Arthur B. Cohen and Joseph P. Healey

     

     

     

    Exhibit 99.1

     

    JOINT FILING AGREEMENT

     

    In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Class A common stock, $0.0001 par value per share, of Hyperfine, Inc., and further agree that this Joint Filing Agreement shall be included as an exhibit to such joint filings.

     

    The undersigned further agree that each party hereto is responsible for the timely filing of such Statement on Schedule 13G and any amendments thereto, and for the accuracy and completeness of the information concerning such party contained therein; provided, however, that no party is responsible for the accuracy or completeness of the information concerning any other party, unless such party knows or has reason to believe that such information is inaccurate.

     

    This Joint Filing Agreement may be signed in counterparts with the same effect as if the signature on each counterpart were upon the same instrument.

     

      HC Sponsor LLC
       
      By: /s/ Christine Clarke
      Name: Christine Clarke
      Title: Authorized Signatory
       
      HealthCor Group, LLC
       
      By: /s/ Christine Clarke
      Name: Christine Clarke
      Title: Authorized Signatory
       
      /s/ Arthur B. Cohen
      Arthur B. Cohen
       
      /s/ Joseph P. Healey
      Joseph P. Healey

     

     

     

    Get the next $HYPR alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $HYPR

    DatePrice TargetRatingAnalyst
    8/11/2022$8.00 → $2.40Overweight → Equal Weight
    Wells Fargo
    5/31/2022$7.00Outperform
    Evercore ISI
    4/14/2022$8.00Overweight
    Wells Fargo
    More analyst ratings

    $HYPR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Hyperfine Announces Key Executive Appointments to Strengthen its Leadership Position in AI-Powered Portable MRI

      Rafael O'Halloran, PhD, and Rob Fasciano, PhD, bring depth and breadth of experience in imaging and Medtech. Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—announced the appointments of Rob Fasciano, PhD, as Chief Regulatory and Quality Officer, and Rafael O'Halloran, PhD, as Vice President of Technology. These leadership additions were instrumental in the development of the recently FDA-cleared Optive AI™ software and the new, next-generation Swoop® scanner. Their work will greatly aid the rollout of this new technology globally and the d

      6/11/25 9:00:00 AM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Hyperfine Announces FDA Clearance of a New Next-Generation Swoop® System Powered by Optive AI™ Software, Delivering a Transformative Leap in Image Quality

      This major Swoop® system scanner redesign and Optive AI™ software elevate the AI-powered portable MRI experience for clinicians and their patients across multiple sites of care. Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—announced today FDA clearance of its most significant technological advancement to date. The clearance includes an entirely new portable MRI scanner powered by the proprietary Optive AI™ software. This new system delivers the highest level of image quality, functionality, and usability to date, unlocking a new brain im

      6/2/25 8:15:00 AM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Hyperfine Announces FDA Clearance of Optive AI™ Software, Introducing the Most Substantial Image Quality Improvement Ever for the Swoop® System

      Latest Swoop® System software delivers a substantial leap in image quality for AI-powered portable MR brain imaging. Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the world's first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced FDA clearance of its next-generation software. This tenth-generation release delivers a substantial leap in image quality for ultra-low-field MR imaging. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250528571999/en/Comparison of Swoop® system FLAIR images showing current image quality and ne

      5/28/25 9:00:00 AM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $HYPR
    SEC Filings

    See more
    • SEC Form 8-K filed by Hyperfine Inc.

      8-K - Hyperfine, Inc. (0001833769) (Filer)

      5/23/25 5:00:17 PM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Hyperfine Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Hyperfine, Inc. (0001833769) (Filer)

      5/19/25 4:15:00 PM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 424B5 filed by Hyperfine Inc.

      424B5 - Hyperfine, Inc. (0001833769) (Filer)

      5/13/25 4:25:28 PM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $HYPR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Hyperfine downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded Hyperfine from Overweight to Equal Weight and set a new price target of $2.40 from $8.00 previously

      8/11/22 6:32:27 AM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Evercore ISI initiated coverage on Hyperfine with a new price target

      Evercore ISI initiated coverage of Hyperfine with a rating of Outperform and set a new price target of $7.00

      5/31/22 7:16:51 AM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Wells Fargo initiated coverage on Hyperfine with a new price target

      Wells Fargo initiated coverage of Hyperfine with a rating of Overweight and set a new price target of $8.00

      4/14/22 7:32:25 AM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $HYPR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Wolterman Dan

      4 - Hyperfine, Inc. (0001833769) (Issuer)

      6/6/25 4:01:04 PM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • CFO and CAO Hale Brett was granted 300,000 shares (SEC Form 4)

      4 - Hyperfine, Inc. (0001833769) (Issuer)

      5/20/25 5:26:31 PM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chief Operating Officer Teisseyre Thomas was granted 300,000 shares, increasing direct ownership by 365% to 382,213 units (SEC Form 4)

      4 - Hyperfine, Inc. (0001833769) (Issuer)

      5/20/25 5:24:42 PM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $HYPR
    Leadership Updates

    Live Leadership Updates

    See more
    • QuidelOrtho Announces Appointment of Two Independent Directors to its Board

      Veteran Healthcare CEOs John R. Chiminski and R. Scott Huennekens Bring Deep Industry Experience, Operational Expertise and Financial Acumen to the QuidelOrtho Board QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced the appointments of John R. Chiminski and R. Scott Huennekens to its board of directors (the "Board"), effective December 6, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241210769572/en/R. Scott Huennekens (Photo: Business Wire) T

      12/10/24 7:00:00 AM ET
      $CTLT
      $HYPR
      $NVST
      $QDEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Medical/Dental Instruments
    • Hyperfine Announces Strategic Leadership Additions to Drive Growth in Key Business Verticals

      Two new executive roles position Hyperfine to drive the adoption of the Swoop® system in hospital settings and expand into the office setting, laying the foundation for significant growth in 2025 and beyond. Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced the appointment of Chi Nguyen as Vice President of Office Strategy and Partnerships and Rafael Donnay as Vice President of Hospital Strategy and Health Economics to provide leadership in key growth areas. These strategic leadership appointments bolster t

      12/3/24 9:00:00 AM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Hyperfine, Inc. Continues Global Market Expansion by Entering Into a Distribution Partnership with Radiosurgery Global, Ltd. to Bring the Swoop® System to India

      Strategic focus on India aims to make the Swoop® portable MR brain imaging system commercially available in a vast and underserved MRI market Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced it has entered into a distribution agreement with Radiosurgery Global, Ltd. to develop the market in India. The distribution agreement also includes the countries of Malaysia, Indonesia, and Singapore through future expansion, offering Hyperfine, Inc. a significantly increased presence in Asia. The clinical value of the Swoop®

      5/28/24 9:00:00 AM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $HYPR
    Financials

    Live finance-specific insights

    See more
    • Hyperfine, Inc. to Announce First Quarter 2025 Financial Results on May 13, 2025

      Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced that it will report financial results for the first quarter 2025 on Tuesday, May 13, 2025. Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A live audio webcast and an archive of the recording will be available through the Investors page of Hyperfine, Inc.'s corporate website at https://investors.hyperfine.io/. Participants are encouraged to register more than 15 minutes before the start of the call. About the Swo

      4/29/25 4:28:00 PM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Hyperfine, Inc. to Announce Fourth Quarter and Full Year 2024 Financial Results on March 17, 2025

      Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced that it will report financial results for the fourth quarter and full year 2024 on Monday, March 17, 2025. Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A live audio webcast and an archive of the recording will be available through the Investors page of Hyperfine, Inc.'s corporate website at https://investors.hyperfine.io/. Participants are encouraged to register more than 15 minutes before the start of the call

      3/4/25 4:05:00 PM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Hyperfine, Inc. Reports Third Quarter 2024 Financial Results

      GUILFORD, Connecticut, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced third quarter 2024 financial results and provided a business update. "The Hyperfine team delivered yet another strong quarter of financial performance across revenue growth, gross margin expansion, and disciplined cash management while executing against several important priorities in our plans to expand into new sites of care and internationally," said Maria Sainz, Chief Executive Officer and President of Hy

      11/12/24 4:05:00 PM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $HYPR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Hyperfine Inc.

      SC 13G - Hyperfine, Inc. (0001833769) (Subject)

      2/13/24 5:06:19 PM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by Hyperfine Inc. (Amendment)

      SC 13G/A - Hyperfine, Inc. (0001833769) (Subject)

      2/14/23 4:07:09 PM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by Hyperfine Inc. (Amendment)

      SC 13G/A - Hyperfine, Inc. (0001833769) (Subject)

      12/20/22 4:22:37 PM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care